Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: A systematic review and trial sequential analysis

详细信息    查看全文

• 作者：Nelson Wang^a ; Pierre Qian^b ; Tristan D. Yan^a ; Kevin Phan^a ; ^b ; ^{kphan.vc@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Acute kidney injury ; Contrast ; Percutaneous coronary intervention ; Angioplasty ; Meta-analysis ; Trial sequential analysis
• 刊名：International Journal of Cardiology
• 出版年：2016
• 出版时间：1 March 2016
• 年：2016
• 卷：206
• 期：Complete
• 页码：143-152
• 全文大小：1669 K

文摘

Contrast-induced acute kidney injury (CI-AKI) is a potential complication in coronary angiography (CAG) and percutaneous coronary interventions (PCI). Prior randomized controlled trials (RCTs) have suggested that statins may play a role in reducing rates of CI-AKI, however it is not clear how firm the current evidence is.

Objectives

The aim of this study was to conduct a meta-analysis and trial sequential analysis to determine the effects of statins in lowering CI-AKI rates in CAG and PCI.

Methods

A systematic literature search was performed to include all RCTs comparing statins (treatment arm) versus low-dose statins or placebo (control arm) as pretreatment for CAG and/or PCI. A traditional meta-analysis and several subgroup analyses were conducted using traditional meta-analysis with relative risk (RR), trial sequential analysis, and meta-regression analysis.

Results

14 RCTs met our inclusion criteria giving a total of 2992 statin treated (49.6%) and 3041 control patients (50.4%). There was a significant reduction in CI-AKI in the statin group compared to controls (3.7% vs 8.3%, RR, 0.46; p = < 0.00001). Trial sequential analysis using a relative risk reduction threshold of 20%, power 80% and type 1 error of 5%, indicated that the evidence is firm. A greater risk reduction in CI-AKI in the statin group significantly correlated with higher estimated glomerular filtration rate (eGFR; p = 0.003)

Conclusions

The present trial sequential analysis provides support for statins in reducing the incidence of CI-AKI in patients undergoing CAG/PCI. This effect appeared to be greater in patients with higher eGFR.